Ruuskanen O, Lahti E, Jennings L, Murdoch D. Viral pneumonia. Lancet. 2011;377:1264-1275. doi: 10.1016/S0140-6736(10)61459-6   Vigant F, Santos N, Lee B. Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol. 2015;13:426-437. doi: 10.1038/nrmicro3475   Jiang D, Ni D, Rosenkrans Z, Huang P, Yan X, Cai W. Nanozyme: New horizons for responsive biomedical applications. Chem Soc Rev. 2019;48:3683-3704.   Wang H, Wan K, Shi X. Recent advances in nanozyme research. Adv Mater. 2019;31:e1805368. doi: 10.1002/adma.201805368   Peng W, Tai W, Li B, et al. Inhalable nanocatalytic therapeutics for viral pneumonia. Nat Mater. 2024. doi: 10.1038/s41563-024-02041-5   Bai X, Chen Q, Li F, et al. Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy. Nat Commun. 2024;15:6844. doi: 10.1038/s41467-024-51056-8   Ye T, Jiao Z, Li X, et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature. 2023;624:630-638. doi: 10.1038/s41586-023-06809-8   Li J, Wu S, Guo X, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: A randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10:739-748. doi: 10.1016/S2213-2600(22)00087-X